Johnson & Johnson Newsroom

Johnson & Johnson To Go Ex-Dividend On November 26th, 2024 With 1.24 USD Dividend Per Share

November 24th (Eastern Time) - $Johnson & Johnson(JNJ.US)$ is trading ex-dividend on November 26th, 2024.Shareholders of record on November 26th, 2024 will receive 1.24 USD dividend per share on

Futu NewsNov 25 09:00

Johnson & Johnson (JNJ.US) has submitted a regulatory application to the FDA for its antibody therapy to treat moderate to severe active ulcerative colitis.

Johnson & Johnson (JNJ.US) announced that it has submitted a supplemental Biological Product License Application (sBLA) to the FDA in the USA.

Zhitong FinanceNov 24 16:51

Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch

Yahoo FinanceNov 23 23:16

Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC

Seeking AlphaNov 23 10:25

Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program

Seeking AlphaNov 23 00:50

Express News | Johnson & Johnson is seeking approval from the FDA to use the subcutaneous induction therapy of TREMFYA (GUSELKUMAB) to treat ulcerative colitis.

BreakingsNov 23 00:38

Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis

MT NewswiresNov 22 21:47

Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and Others

Seeking AlphaNov 22 21:40

Express News | Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya® (Guselkumab) in Ulcerative Colitis, a First for an Il-23 Inhibitor

BreakingsNov 22 21:00

Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days

Simply Wall StNov 22 20:18

Zevra Niemann-Pick Disease Type C Drug Miplyffa Now Available

Seeking AlphaNov 22 06:29

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are...

BenzingaNov 22 05:14

Express News | Health Canada Authorizes Carvykti® (Ciltacabtagene Autoleucel) for Patients With Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

BreakingsNov 22 05:00

Optimism Over Global Healthcare Sector Rises: Jefferies

Seeking AlphaNov 22 02:45

Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity

BenzingaNov 22 01:03

Price Over Earnings Overview: Johnson & Johnson

BenzingaNov 21 21:00

Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.

Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.

cls.cnNov 21 13:34

J&J Loses Around $24B in a Month: How to Play the Stock?

Zacks Nov 21 03:30

Sector Update: Health Care Stocks Advance Wednesday Afternoon

MT NewswiresNov 21 03:00

U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks

BenzingaNov 21 02:28